Existing agents, novel agents, or transplantation for high-risk MDS
The decision algorithm for treatment of advanced myelodysplastic syndrome (MDS) (intermediate- to very high-risk by the revised International Prognostic Scoring System
Myelodysplastic Syndromes (MDS)
Therapy for lower-risk MDS
Lower-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders whe
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
This study investigated the efficacy and safety of azacitidine azacitidine: It works by reducing the amount of methylation in the body.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative option for myelodysplastic syndromes myelodysplast
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
We conducted a prospective observational study of fit adults aged 60-75 with advanced MDS, enrolled hierarchically for adverse MDS risk (intermediate-2 or high-risk international prognostic score [IPSS], low or intermediate-1 IPSS with poor-risk cytogenetics
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map
Heterogeneity is the disease-defining epithet of myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-ti
The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications
The molecular pathogenesis of myelodysplastic syndrome (MDS) is complex due to the high rate of genomic heterogeneity. Significant advances have been made in the last decade which elucidated the landscape of molecular alterations (cytogenetic abnormalities, gene mutations) in MDS.
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
Treatment with hypomethylating agents (HMAs) azacitidine azacitidine: It works by reducing the amount of methylation in the body.